Head to Head Review: TNF Pharmaceuticals (NASDAQ:TNFA) & Cardio Diagnostics (NASDAQ:CDIO)

Cardio Diagnostics (NASDAQ:CDIO) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 1.2% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cardio Diagnostics and TNF Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$34,890.00	493.20	-$8.38 million	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$4.00 million	N/A	N/A

TNF Pharmaceuticals has lower revenue, but higher earnings than Cardio Diagnostics.

Profitability

This table compares Cardio Diagnostics and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-22,732.03%	-258.85%	-191.20%
TNF Pharmaceuticals	N/A	-180.71%	-84.27%

Analyst Recommendations

This is a breakdown of current ratings for Cardio Diagnostics and TNF Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0	0	1	0	3.00
TNF Pharmaceuticals	0	0	0	0	0.00

Cardio Diagnostics presently has a consensus target price of $2.00, indicating a potential upside of 506.06%. Given Cardio Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardio Diagnostics is more favorable than TNF Pharmaceuticals.

Risk and Volatility

Cardio Diagnostics has a beta of 3.61, meaning that its share price is 261% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.

Summary

Cardio Diagnostics beats TNF Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.